H.C. Wainwright lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 111 from SEK 132 and keeps a Buy rating on the shares after Imlifidase failed in the Phase 3 study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNSBF: